- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06308029
Effectiveness of an eHealth Self-management Support Program for Persistent Pain After Breast Cancer Treatment (PECAN)
The scientific goals of the project are:
The primary scientific objective of the study is to determine the effectiveness of an eHealth self-management support program for persistent pain after breast cancer treatment compared to:
- usual care (i.e. superiority of the eHealth self-management support program) and
- a comprehensive pain rehabilitation program delivered face-to-face in a physical therapy setting (i.e. non-inferiority of the eHealth self-management support program)
on pain-related disability (measured with the Pain Disability Index).
The secondary scientific objectives of this study entails to examine if the eHealth self-management support program has a relative benefit for other biopsychosocial factors, including:
- Other dimensions of pain
- Health-related quality of life
- Physical functioning, including physical activity levels
- Psychosocial functioning, including self-efficacy, stress, anxiety, depression, coping style (key secondary outcome) and fear of cancer recurrence
- Participation in society, including return to work
- Healthcare-related costs for the patient and society
The tertiary scientific objectives of this study are
- to identify moderators of treatment effect, including behavioural determinants (e.g. self-efficacy, motivation, coping style), in order to identify breast cancer survivors who would benefit the most of the eHealth self-management support program and to allow more stratified and efficient pain management care and more targeted allocation of budgets.
- To examine the implementation process, mechanisms of impact and contextual factors.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: An De Groef, PhD
- Phone Number: 003216342171
- Email: an.degroef@uantwerpen.be
Study Contact Backup
- Name: Lore Dams, PhD
- Email: lore.dams@uantwerpen.be
Study Locations
-
-
-
Antwerpen, Belgium
- Recruiting
- Universiteit Antwerpen
-
Contact:
- Lore Dams, PhD
- Email: lore.dams@uantwerpen.be
-
Contact:
- An De Groef, PhD
- Email: an.degroef@uantwerpen.be
-
Leuven, Belgium
- Recruiting
- KU Leuven
-
Contact:
- An De Groef, PhD
- Email: an.degroef@kuleuven.be
-
Contact:
- Nele Devoogdt, PhD
- Email: nele.devoogdt@kuleuven.be
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion criteria
- Patients (men and women) with primary breast cancer and with unilateral or bilateral axillary surgery (Axillary Lymph Node Dissection or Sentinel Node Biopsy);
- Be in complete remission and should have finished their primary treatment with a curative intent at least 3 months prior to study participation;
- Adjuvant hormonal therapy and immunotherapy form the exception to the rule are tolerated;
- Presence of self-reported persistent pain in the last 3 months that interferes with daily activities (yes/no)
Exclusion criteria
- Can not participate during the entire study period;
- Mentally or physically unable to participate in the study;
- Previous participation in a pain science education program.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: eHealth self-management support program
This web-based eHealth program consists of two parts.
First participants will complete a pain science education program.
After being primed in the educational program, barriers for a physically active lifestyle should be removed and participants should be able to apply the learned information in the second part.
The second part of the self-management support program consists of daily activity planning and strategies to promote an active lifestyle.
|
This web-based eHealth program consists of two parts.
First participants will complete a pain science education program.
After being primed in the educational program, barriers for a physically active lifestyle should be removed and participants should be able to apply the learned information in the second part.
The second part of the self-management support program consists of daily activity planning and strategies to promote an active lifestyle.
The eHealth program will be accessible from any digital device (laptop, tablet, smartphone) after receiving a personal login code provided by the researcher.
Participants go through the eHealth program independently at their own pace.
It is recommended to do this in 8-12 weeks.
|
Active Comparator: Face-to-face rehabilitation program
The face-to-face rehabilitation program combines pain science education with an active behavioral approach.
First, 2-3 individual face-to-face sessions are organized with a physical therapist (recruited and trained by the research team) to provide pain science education.
The content of this pain science education program is the same as for the eHealth program.
Similar as in the eHealth program, this education intervention includes advice for activity management, while experiencing pain and other symptoms, in order to remove barriers for an active lifestyle.
The educational information will be presented verbally (explanation by the therapist) and written (information leaflet, summaries, pictures, metaphors and diagrams on computer and paper).
After the education, the physical therapist will discuss proper goal setting with the patient to reach an active lifestyle and will coach the participant to reach these goals with maximum 6 face-to-face sessions.
|
The face-to-face rehabilitation program combines pain science education with an active behavioral approach.
First, 2-3 individual face-to-face sessions are organized with a physical therapist to provide pain science education.
The content of this pain science education program is the same as for the eHealth program.
Similar as in the eHealth program, this education intervention includes advice for activity management, while experiencing pain and other symptoms, in order to remove barriers for an active lifestyle.
The educational information will be presented verbally and written.
After the education, the physical therapist will discuss proper goal setting with the patient to reach an active lifestyle and will coach the participant to reach these goals with maximum 6 face-to-face sessions.
It is recommend to organise the in total 9 face-to-face sessions within a periode of 8-12 weeks.
|
No Intervention: Usual care group
Usual care for breast cancer survivors with persistent pain consists of primarily a pharmacological approach and general advice to stay or become active.
This information is given to the participant by means of a brochure.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain-related disability
Time Frame: at 6 months follow-up
|
Measured with Pain Disability Index, an instrument for measuring the impact that pain has on the ability of a person to participate in essential life activities.
Scores between 0 and 70.
The higher the score the greater the person's disability due to pain.
The trial will be termed successful when superiority of the eHealth self-management to usual care and non-inferiority of the eHealth self-management program to face-to face rehabilitation program has been shown for the primary outcome at 6 months.
Both tests will be based on the comparison of the mean value after correction for the baseline PDI (ANCOVA approach).
|
at 6 months follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pain related disability
Time Frame: at 12 weeks and 12 months follow-up
|
Measured with Pain Disability Index, an instrument for measuring the impact that pain has on the ability of a person to participate in essential life activities.
Scores between 0 and 70.
The higher the score the greater the person's disability due to pain
|
at 12 weeks and 12 months follow-up
|
Medication use
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
self-composed questionnaire
|
at 12 weeks, 6 months and 12 months follow-up
|
Pain location
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
Margolis Pain Diagram
|
at 12 weeks, 6 months and 12 months follow-up
|
Knowledge of neurophysiology of pain
Time Frame: at 6 weeks
|
measured with the Neurophysiology of Pain Test
|
at 6 weeks
|
Return to work rate
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
measured with a self-composed questionnaire
|
at 12 weeks, 6 months and 12 months follow-up
|
Pain severity
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
Measured with a Visual Analogue Scale (0-100), a higher score indicates more severe pain.
|
at 12 weeks, 6 months and 12 months follow-up
|
Severity of neuropathic Pain
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
Measured with the Neuropathic Pain Symptom Inventory (0-100), a higher score indicates more severe pain.
|
at 12 weeks, 6 months and 12 months follow-up
|
Physical Activity pattern
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
measured with the Patterns of Activity Measure - Pain (short form).
It measures 3 pain-related activity patterns: avoidance, overdoing, and pacing.
Potential scores on each of the 3 POAM-P scales can range from 0 to 20.
Higher scores in any pattern indicate more of the measured construct.
|
at 12 weeks, 6 months and 12 months follow-up
|
Physical functioning
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
measured with the Patient-Reported Outcomes Measurement Information System (PROMIS)-57 Profile v2.01.
Each domain of the PROMIS-57 is expressed as a score compared to the average of a group (T-score).
A T-score is a standardized score.
The average score in a population is assigned the value 50.
The standard deviation becomes equated to 10 points.
|
at 12 weeks, 6 months and 12 months follow-up
|
Fatigue
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
measured with the Patient-Reported Outcomes Measurement Information System( PROMIS)-57 Profile v2.01.
Each domain of the PROMIS-57 is expressed as a score compared to the average of a group (T-score).
A T-score is a standardized score.
The average score in a population is assigned the value 50.
The standard deviation becomes equated to 10 points.
|
at 12 weeks, 6 months and 12 months follow-up
|
Sleep disturbance
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
measured with the Patient-Reported Outcomes Measurement Information System (PROMIS)-57 Profile v2.01.
Each domain of the PROMIS-57 is expressed as a score compared to the average of a group (T-score).
A T-score is a standardized score.
The average score in a population is assigned the value 50.
The standard deviation becomes equated to 10 points.
|
at 12 weeks, 6 months and 12 months follow-up
|
Pain Beliefs
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
Measured with the Survey of Pain Attitudes (SOPA)-short form.
It contains seven subscales including 30 items in total with a 5-item Likert scale.
Each domain of the SOPA is expressed as a score compared to the average of a group (T-score).
|
at 12 weeks, 6 months and 12 months follow-up
|
Pain-related worrying
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
Measured with the Pain Catastrophizing Scale.
Thirteen items are scored on a 5-item Likert scale ranging from "not" to "always".
The total score ranges from 0 to 52, where higher scores are associated with higher levels of catastrophizing.
|
at 12 weeks, 6 months and 12 months follow-up
|
Vigilance to bodily sensations
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
Measured with the Bodily Threat Monitoring Scale.
This is a new 19-item self-report measure that captures the tendency to monitor and interpret bodily sensations as symptomatic of something being wrong with one's body.
Scores range from 0 to 76, with higher scores indicating greater bodily threat monitoring.
|
at 12 weeks, 6 months and 12 months follow-up
|
Depression
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
measured with the Patient-Reported Outcomes Measurement Information System (PROMIS)-57 Profile v2.01.Each domain of the PROMIS-57 is expressed as a score compared to the average of a group (T-score).
A T-score is a standardized score.
The average score in a population is assigned the value 50.
The standard deviation becomes equated to 10 points.
|
at 12 weeks, 6 months and 12 months follow-up
|
Anxiety
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
measured with the Patient-Reported Outcomes Measurement Information System (PROMIS)-57 Profile v2.01.
Each domain of the PROMIS-57 is expressed as a score compared to the average of a group (T-score).
A T-score is a standardized score.
The average score in a population is assigned the value 50.
The standard deviation becomes equated to 10 points.
|
at 12 weeks, 6 months and 12 months follow-up
|
Determinants for physical activity
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
measured with the Determinants of Physical Activity Questionnaire.
Each item was assessed using a 7-point scale for all determinants of physical activity.
Lower scores indicate low exercisers, while high scores indicate high exercisers.
|
at 12 weeks, 6 months and 12 months follow-up
|
Participation
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
measured with the PROMIS-57 Profile v2.01.
Each domain of the PROMIS-57 is expressed as a score compared to the average of a group (T-score).
A T-score is a standardized score.
The average score in a population is assigned the value 50.
The standard deviation becomes equated to 10 points.
|
at 12 weeks, 6 months and 12 months follow-up
|
Well-being
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
measured with the Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health.
Each domain of the PROMIS is expressed as a score compared to the average of a group (T-score).
A T-score is a standardized score.
The average score in a population is assigned the value 50.
The standard deviation becomes equated to 10 points.
|
at 12 weeks, 6 months and 12 months follow-up
|
Social Support
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
measured with the Patient-Reported Outcomes Measurement Information System (PROMIS)-57 Profile v2.01.
Each domain of the PROMIS-57 is expressed as a score compared to the average of a group (T-score).
A T-score is a standardized score.
The average score in a population is assigned the value 50.
The standard deviation becomes equated to 10 points.
|
at 12 weeks, 6 months and 12 months follow-up
|
Medical costs of medical consumption
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
measured with the Medical Consumption Questionnaire.
The costs of medical consumption are calculated by measuring the volumes of care multiplied by the cost price per unit of care.
|
at 12 weeks, 6 months and 12 months follow-up
|
Indirect costs related to disease outside health care
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
measured with the Productivity Cost Questionnaire.
To calculate the costs of production losses, volumes are multiplied with unit costs.
|
at 12 weeks, 6 months and 12 months follow-up
|
Health-related quality of life
Time Frame: at 12 weeks, 6 months and 12 months follow-up
|
measured with the EuroQol-5Dimensions-5Levels (EQ-5D-5L) questionnaire.
The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.
This decision results in a 1-digit number that expresses the level selected for that dimension.
The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Standard EQ-5D-5L value sets are available for different regions.
The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can image' and 'The worst health you can image'.
The VAS can be used as a quantitative measure of health outcome that reflects the patient's own judgement.
|
at 12 weeks, 6 months and 12 months follow-up
|
Patient Global Impression of Change
Time Frame: at 12 weeks follow-up
|
measured with the Patient Global Impression of Change (PGIC).
PGIC is a 7 point scale depicting a patient's rating of overall improvement.
Patients rate their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."
|
at 12 weeks follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: An De Groef, PhD, Universiteit Antwerpen
- Principal Investigator: Nele Devoogdt, PhD, KU Leuven
- Principal Investigator: Geert Crombez, PhD, UGent
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Edge003203
- T001122N (Other Grant/Funding Number: Research Foundations Flanders)
- s68058 (Other Identifier: UZ/KU Leuven ID)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on eHealth self-management support program
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedChronic Obstructive Pulmonary Disease | Type 2 DiabetesNetherlands
-
National Taipei University of Nursing and Health...Mackay Memorial Hospital; Ministry of Science and Technology, Taiwan; Cathay...RecruitingColorectal NeoplasmsTaiwan
-
Laval UniversityQuebec Pain Research NetworkRecruiting
-
University of Colorado, DenverCompletedDiabetes Complications | Peripheral Arterial DiseaseUnited States
-
Oslo University HospitalUniversity of Oslo; Sunnaas Rehabilitation Hospital; South-Eastern Norway Regional...RecruitingTrauma Injury | Trauma, Multiple | PolytraumaNorway
-
Omada Health, Inc.Palo Alto Medical Foundation; Sutter HealthTerminatedType 2 DiabetesUnited States
-
University of Southern DenmarkZealand University Hospital; Holbaek Sygehus; Naestved Hospital; Nykøbing Falster... and other collaboratorsActive, not recruitingDepression | Heart Failure | Hypertension | Chronic Obstructive Pulmonary Disease | Osteoarthritis, Knee | Coronary Heart Disease | Osteoarthritis, Hip | Type2 DiabetesDenmark
-
Radboud University Medical CenterCompleted
-
University of StavangerHelse Stavanger HF; St. Olavs HospitalRecruitingHeart Failure | Colon Rectal Cancer | Non Communicable DiseasesNorway
-
University of North Carolina, Chapel HillCenters for Disease Control and PreventionCompletedChronic DiseaseUnited States